Business Wire

Tallence Selects Radisys’ Engage Platform as Foundation for New Cloud Messaging Solution

16.12.2020 16:00:00 EET | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today announced that Tallence AG, a digital transformation technology and management consultancy, has selected Radisys’ Engage Media Server as the foundation for a new voice messaging system for a Tier 1 European operator. Tallence will leverage the extensive capabilities of the Engage Media Server, a foundational element of the Radisys Engage communications services enablement platform, to create enhanced digital customer experiences with high quality interactions and augment content to create greater customer satisfaction and increase customer loyalty.

Highlights

  • Digital communications solutions continue to become more integrated into both mobile and web paths of the customer journey. The COVID-19 pandemic is accelerating the shift in customer experience to online solutions. Application developers and Communication Service Providers (CSPs) must be able to quickly bring online new, scalable and elastic services that can be adapted to changing market conditions. With the right platform, they can meet the combined challenges of rapid increases and fluctuations in customer access traffic and increasingly remote, distributed workforces, all while enabling a top quality seamless experience.
  • Traditionally, only large enterprises had the infrastructure and budgets to deliver compelling digital experiences that seamlessly tie voice and video interaction with content and business processes. By migrating these services to the cloud on the foundation of Radisys’ Engage Media Server, Tallence is providing services that enable businesses of all sizes to reach their consumers at lower cost, with greater flexibility, and optimal use of resources.
  • Radisys’ Engage Media Server delivers a rich set of media capabilities for developers and CSPs to create enhanced and engaging digital customer experiences. It provides the foundation for high-value voice and video features to enrich digital experience applications, and it enables CSPs to leverage the cloud for low cost and increased efficiency with industry-leading capacities for best total cost of ownership. The cloud-based Engage Media Server delivers:
    • On demand scalability which reduces costs for broad market reach for digital experience applications and services at attractive price points.
    • Optimal user experiences that tie to brand and customer satisfaction by using high quality voice and video, including real-time processing for 4G and 5G, PSTN, and web or mobile app modalities that can adapt to various bandwidth and network conditions and ensure CSPs can meet even the most rigorous availability and quality service level agreements with their customers.
    • Powerful tools for application developers to quickly bring to market applications and services and on-demand adaptation for new campaigns through industry-leading analytics.

“Radisys’ Engage Media Server delivers the scalability and capabilities required for exceptional digital experience-related services for our new cloud-based voice messaging solution deployed for our tier-one customer,” said Christian Schöntag, Head of Consulting, Tallence AG. “Furthermore, Radisys’ extensive experience in cloud-based media processing is critical for enabling us to ensure reliability and scalability for our customers as they accelerate their move to the cloud.”

“Tallence AG has an impressive reputation in delivering innovative customer experiences that can provide compelling ROIs for their customers and sticky, loyalty building experiences for their end users,” said Al Balasco, Radisys’ Head of Media, Core and Applications Business. “Our Engage platform is deployed by over 150 operators and currently serves 2 billion users worldwide. Tallence’s cloud-based application builds on this mobile network-optimized platform to deliver services for a new age and represents the value of our media server to leading solution providers in enabling digital consumer experiences and e-commerce services.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

About Tallence

Tallence AG is a technology and management consultancy for digital transformation. We support our customers in using digitalization to their advantage and creating competitive advantages. We advise, develop and manage with a hands-on and result-oriented approach. Whether international technology group, traditional medium-sized enterprises or public sector: The benefit for the end customer is always the guiding principle and driving force behind Tallence. We ensure this through genuine expert performance and the highest level of commitment. Our clients come from diverse industries including telecommunications, information, media and energy. At Tallence AG more than 150 IT developers, machine learning specialists and management consultants based in our German office locations in Hamburg, Frankfurt, Marburg, Görlitz and Karlsruhe are working on future-oriented topics of the Digital Economy. Read more on: www.tallence.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye